Table 1.
Effect of G protein-coupled receptor kinase 2 inhibition on terbutaline-sensitive alveolar fluid clearance at day 2 after RSV infection.
| Treatment | Conc. (μM) | n* | % AFC30† | ΔTERBUT (%)‡ |
|---|---|---|---|---|
| None | - | 10 | 21.8 ± 2.3 | - |
| Terbutaline | 100 | 17 | 24 ± 2.3 | 10 |
| GRK2 inhibitor (GRK2i) | 100 | 10 | 23.4. ± 2.1 | - |
| GRK2i + Terbutaline | 100 + 100 | 8 | 32.9 ± 2.2 §# | 50 |
| GRK2i + Terbutaline + Amiloride | 100 + 100 + 1500 | 7 | 19. 6 ± 1.9 | −11 |
| GRK2i + Terbutaline + 14–22 Amide | 100 + 100 + 100 | 6 | 19.9 ± 2.1 | −9 |
*
Number of mice in which AFC was evaluated
†
Mean % AFC ± SEM
‡
% change in mean AFC with terbutaline
§
% AFC30 in mock-infected mice is 34.8 ± 1.5 (n=11) (from ref. 4)
#
P<0.05 versus untreated AFC at day 2